Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Down 44.8% in March

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 28,600 shares, a drop of 44.8% from the March 15th total of 51,800 shares. Based on an average trading volume of 73,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Stock Performance

OTCMKTS FSNUY traded down $0.08 on Friday, reaching $11.11. 33,745 shares of the company's stock traded hands, compared to its average volume of 62,994. Fresenius SE & Co. KGaA has a fifty-two week low of $7.11 and a fifty-two week high of $11.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The firm has a market cap of $24.82 billion, a price-to-earnings ratio of 52.90 and a beta of 0.86. The stock has a 50 day moving average price of $10.50 and a 200-day moving average price of $9.58.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The firm had revenue of $6.01 billion for the quarter. Equities research analysts predict that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.